Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thromboprophylaxis After Gynecologic Malignancy Surgery
NCT02935530Phase 3Completed
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of argatroban and low molecular weight heparin calcium in venous thromboembolism (VTE) (3 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Venous Thromboembolism Rate at 30 days. Started Jan 2016; status: completed.
02
Drugs
argatrobanlow molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02935530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935530.